Shankar Vallabhajosula

Vice President, Radiopharmaceutical Sciences Convergent Therapeutics

Dr. Vallabhajosula is a Professor Emeritus of radiochemistry/radiopharmacy in radiology at Weill Cornell Medicine (WCM), New York, NY. He also served as the president and chief scientific officer (CSO) for four years at NCM USA, a radiopharmaceutical manufacturing company for PET and TRT. At this time, he is the vice president of Radiopharmaceutical sciences at Convergent Therapeutics Inc., Cambridge, MA. Shankar published more than 130 articles in major scientific journals and was responsible for obtaining more than twenty investigational new drugs (INDs) for PET and TRT. positron emission tomography (PET) and therapeutic radiopharmaceuticals. He published two single author textbooks; “Molecular Imaging: Radiopharmaceuticals for PET and SPECT” (Springer Verlag, 2009). A second and revised edition “Molecular Imaging and Targeted Therapy: Radiopharmaceuticals and Clinical Applications” (Springer Nature 2023).

Seminars

Thursday 25th February 2027
Comparing Dosimetry Considerations Across Alpha & Beta Emitters to Inform Therapeutic Development
2:00 pm
  • Benchmark the current state of therapeutic radiopharmaceutical dosimetry to understand what can reliably be measured today & where critical uncertainties remain
  • Examine current regulatory expectations & the limitations of existing dose thresholds to determine what evidence is needed for therapeutic radiopharmaceutical development
  • Explore the path towards more standardized dosimetry approaches that can better connect absorbed dose with clinical outcomes & inform therapeutic development
Shankar Vallabhajosula, Speaker at 3rd TRP Target Selection & Drug Design Summit